Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0B1IC
|
||||
| Former ID |
DIB007423
|
||||
| Drug Name |
CR8020 mab
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Influenza virus [ICD10:J11.1] | Phase 2 | [1] | ||
| Company |
Crucell
|
||||
| Target and Pathway | |||||
| Target(s) | Hemagglutinin | Target Info | [2] | ||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01992276) Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection. U.S. National Institutes of Health. | ||||
| REF 2 | Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol. 2014 Dec;88(23):13580-92. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.